MX2010013978A - 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases. - Google Patents
5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases.Info
- Publication number
- MX2010013978A MX2010013978A MX2010013978A MX2010013978A MX2010013978A MX 2010013978 A MX2010013978 A MX 2010013978A MX 2010013978 A MX2010013978 A MX 2010013978A MX 2010013978 A MX2010013978 A MX 2010013978A MX 2010013978 A MX2010013978 A MX 2010013978A
- Authority
- MX
- Mexico
- Prior art keywords
- acute
- treatment
- chronic inflammatory
- methanesulfonyl
- phenyl
- Prior art date
Links
- 208000030090 Acute Disease Diseases 0.000 title abstract 2
- 230000001154 acute effect Effects 0.000 title abstract 2
- 208000037976 chronic inflammation Diseases 0.000 title abstract 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 title abstract 2
- ZSYQCVZWUMOZJW-UHFFFAOYSA-N 5-(4-methylsulfonylphenyl)-1,3-thiazole Chemical class C1=CC(S(=O)(=O)C)=CC=C1C1=CN=CS1 ZSYQCVZWUMOZJW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 102100037850 Interferon gamma Human genes 0.000 abstract 1
- 108010074328 Interferon-gamma Proteins 0.000 abstract 1
- 108090001007 Interleukin-8 Proteins 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
The invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, in the preparation of a medicament for the treatment of an acute or chronic inflammatory disease, by inhibiting the production of at least one pro-inflammatory cytokine selected from TNF-alpha and IFN-gamma, or by inmunomodulating the IL-8 chemokine and/or the IL-10 regulatory cytokine. The invention also relates to novel compounds of formula (I') or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, as well as a pharmaceutical composition comprising said compound.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/139,661 US7781594B2 (en) | 2008-06-16 | 2008-06-16 | 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases |
| EP08380177A EP2135864A1 (en) | 2008-06-16 | 2008-06-16 | 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases |
| PCT/EP2009/057324 WO2009153226A1 (en) | 2008-06-16 | 2009-06-15 | 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010013978A true MX2010013978A (en) | 2011-03-29 |
Family
ID=43414178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010013978A MX2010013978A (en) | 2008-06-16 | 2009-06-15 | 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases. |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP2313382A1 (en) |
| JP (1) | JP2011524352A (en) |
| KR (1) | KR20110022679A (en) |
| CN (1) | CN102083806A (en) |
| AR (1) | AR072113A1 (en) |
| AU (1) | AU2009259451B2 (en) |
| BR (1) | BRPI0915325A2 (en) |
| CA (1) | CA2728139A1 (en) |
| CO (1) | CO6331429A2 (en) |
| IL (1) | IL209801A0 (en) |
| MA (1) | MA32473B1 (en) |
| MX (1) | MX2010013978A (en) |
| NZ (1) | NZ589894A (en) |
| RU (1) | RU2495031C2 (en) |
| SA (1) | SA109300384B1 (en) |
| TW (1) | TWI403506B (en) |
| UY (1) | UY31896A (en) |
| WO (1) | WO2009153226A1 (en) |
| ZA (1) | ZA201008877B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2961695B1 (en) * | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SKIN DISORDERS |
| RU2502513C2 (en) * | 2012-01-11 | 2013-12-27 | Государственное бюджетное учреждение здравоохранения Свердловской области "Свердловский областной клинический психоневрологический госпиталь для ветеранов войн" (ГБУЗ СО "СОКП Госпиталь для ветеранов войн") | Method of treating patients with multiple organ pathology using ozone therapy |
| SG11202002746YA (en) * | 2017-11-23 | 2020-04-29 | Immunic Ag | Dosage regimen of vidofludimus for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases |
| KR102076936B1 (en) * | 2019-08-12 | 2020-02-13 | 연세대학교 산학협력단 | Composition including thiazole or salt thereof as active ingredients for preventing or treating allergic disease or atopic dermatitis |
| IT202000008125A1 (en) * | 2020-04-16 | 2021-10-16 | Minerva Srl | 3-AZA-BICYCLE CARBOXYLIC ACIDS [3.2.1] OCTANE AND THEIR DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATIONS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0457803A4 (en) * | 1989-02-08 | 1991-12-04 | Abbott Laboratories | 4-hydroxythiazoles as 5-lipoxygenase inhibitors |
| WO1996003392A1 (en) * | 1994-07-27 | 1996-02-08 | G.D. Searle & Co. | Substituted thiazoles for the treatment of inflammation |
| AU6111796A (en) * | 1995-06-12 | 1997-01-09 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor |
| AU7559200A (en) * | 1999-10-12 | 2001-04-23 | Japan Tobacco Inc. | Hypertriglyceridemia remedies and antiobestics |
| CN100502863C (en) * | 2001-08-13 | 2009-06-24 | 詹森药业有限公司 | 2,4, 5-trisubstituted thiazole derivatives and their anti-inflammatory activity |
| US20050026902A1 (en) * | 2003-01-31 | 2005-02-03 | Timothy Maziasz | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents |
-
2009
- 2009-06-06 TW TW098118927A patent/TWI403506B/en not_active IP Right Cessation
- 2009-06-12 UY UY0001031896A patent/UY31896A/en not_active Application Discontinuation
- 2009-06-12 AR ARP090102121A patent/AR072113A1/en unknown
- 2009-06-15 SA SA109300384A patent/SA109300384B1/en unknown
- 2009-06-15 WO PCT/EP2009/057324 patent/WO2009153226A1/en not_active Ceased
- 2009-06-15 NZ NZ589894A patent/NZ589894A/en not_active IP Right Cessation
- 2009-06-15 AU AU2009259451A patent/AU2009259451B2/en not_active Ceased
- 2009-06-15 EP EP09765806A patent/EP2313382A1/en not_active Withdrawn
- 2009-06-15 RU RU2011101439/04A patent/RU2495031C2/en not_active IP Right Cessation
- 2009-06-15 CA CA2728139A patent/CA2728139A1/en not_active Abandoned
- 2009-06-15 KR KR1020117001228A patent/KR20110022679A/en not_active Ceased
- 2009-06-15 CN CN2009801226820A patent/CN102083806A/en active Pending
- 2009-06-15 BR BRPI0915325A patent/BRPI0915325A2/en not_active IP Right Cessation
- 2009-06-15 JP JP2011513001A patent/JP2011524352A/en active Pending
- 2009-06-15 MX MX2010013978A patent/MX2010013978A/en active IP Right Grant
-
2010
- 2010-12-06 IL IL209801A patent/IL209801A0/en unknown
- 2010-12-09 ZA ZA2010/08877A patent/ZA201008877B/en unknown
-
2011
- 2011-01-13 MA MA33516A patent/MA32473B1/en unknown
- 2011-01-14 CO CO11003796A patent/CO6331429A2/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2728139A1 (en) | 2009-12-23 |
| AU2009259451B2 (en) | 2013-03-14 |
| JP2011524352A (en) | 2011-09-01 |
| SA109300384B1 (en) | 2013-04-20 |
| IL209801A0 (en) | 2011-02-28 |
| RU2495031C2 (en) | 2013-10-10 |
| EP2313382A1 (en) | 2011-04-27 |
| BRPI0915325A2 (en) | 2015-10-27 |
| WO2009153226A1 (en) | 2009-12-23 |
| RU2011101439A (en) | 2012-07-27 |
| CO6331429A2 (en) | 2011-10-20 |
| KR20110022679A (en) | 2011-03-07 |
| ZA201008877B (en) | 2012-02-29 |
| AR072113A1 (en) | 2010-08-04 |
| MA32473B1 (en) | 2011-07-03 |
| TW201010988A (en) | 2010-03-16 |
| CN102083806A (en) | 2011-06-01 |
| UY31896A (en) | 2010-01-29 |
| TWI403506B (en) | 2013-08-01 |
| AU2009259451A1 (en) | 2009-12-23 |
| NZ589894A (en) | 2011-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014000341A (en) | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease. | |
| EA201491060A1 (en) | NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE | |
| WO2011107608A8 (en) | Heterocyclic amides as rock inhibitors | |
| UA109421C2 (en) | PHARMACEUTICAL COMPOSITION CONTAINING SIGMA-RECEPTOR LIGANDS | |
| MX2013008673A (en) | Derivatives of azaindazole or diazaindazole type as medicament. | |
| MX2010007375A (en) | Novel lupane derivatives. | |
| MX2009006764A (en) | Bicyclic pyrimidinones and uses thereof. | |
| MX2010007374A (en) | Novel c-21-keto lupane derivatives preparation and use thereof. | |
| MX2009003874A (en) | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents. | |
| MY174002A (en) | Combination theraphy for the treatment of diabetes | |
| TN2010000038A1 (en) | Organic compounds | |
| MX350418B (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders. | |
| WO2008020040A3 (en) | 2,5-dihydroxybenzene compounds for the treatment of fibrosis | |
| JP2013514980A5 (en) | ||
| BR112014001798A2 (en) | substituted 9-aminomethyl tetracycline compounds | |
| IN2012DN02502A (en) | ||
| MX2008016358A (en) | Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors. | |
| MX2010013978A (en) | 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases. | |
| MX2009007038A (en) | Isosorbide mononitrate derivatives for the treatment of intestinal disorders. | |
| WO2010132670A3 (en) | Pentacycline compounds | |
| WO2007095021A3 (en) | Novel compounds | |
| WO2006051314A3 (en) | Guanidine derivatives as inhibitors of ddah | |
| WO2008121859A8 (en) | Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions | |
| WO2012176163A3 (en) | Compounds for the treatment of cancers associated with human papillomavirus | |
| PH12015502560B1 (en) | Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |